FIELD: medicine.
SUBSTANCE: invention relates to method of lupus diagnosing in humans. Present invention involves determining presence of variation of at least in one locus risk SLE, said variation at least in one locus is risk allele of nucleotide polymorphism (SNP). Said variation at least in one locus contains T-allele rs849142 JAZF1. Determination of presence of said variation at least in one locus indicates that individual suffers Erythematosus.
EFFECT: invention can be used for accurate diagnosis of autoimmune disease, such as lupus.
8 cl, 7 dwg, 10 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENETIC POLYMORPHISMS ACCOMPANYING AGE-RELATED MACULAR DEGENERATION | 2010 |
|
RU2546008C2 |
| GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION | 2010 |
|
RU2577726C2 |
| HUMAN GENETIC MARKERS ASSOCIATED WITH RESPONSE TO TREATMENT AGENTS THAT TARGET TOXIN B CLOSTRIDIUM DIFFICILE | 2017 |
|
RU2761249C2 |
| PREDICTION OF PROGRESSION OF AGE-RELATED MACULAR DYSTROPHY TO LATE STAGE BY MEANS OF POLYGENE INDICATOR | 2011 |
|
RU2593954C2 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2008 |
|
RU2482491C2 |
| VEGF POLYMORPHISM AND ANTIANGIOGENESIS THERAPY | 2013 |
|
RU2635525C2 |
| ANALYSIS AND METHOD FOR TREATMENT REGIMEN SELECTION FOR PATIENTS WITH DEPRESSION | 2012 |
|
RU2622082C2 |
| IMPROVED METHOD AND KIT FOR DETERMINING SEVERITY AND PROGRESSION LEVEL OF PERIODONTAL DISEASE | 2011 |
|
RU2664431C2 |
| GENETIC MARKERS FOR PREDICTION OF SUSCEPTIBILITY TO THERAPY | 2014 |
|
RU2707533C2 |
| GENETIC MARKERS FOR PREDICTING SENSITIVITY TO THERAPY | 2014 |
|
RU2809215C2 |
